Achillion Pharmaceuticals on Wednesday announced that two abstracts have been accepted for poster presentation at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA, December 3 – 6, 2016.
“The data to be presented at ASH expand Achillion’s understanding of complement biology and demonstrate the potential advantages of inhibition of factor D in treatment of complement-mediated diseases,” said David Apelian, M.D., Ph.D. and Chief Medical Officer of Achillion Pharmaceuticals. “This and other research recently presented by Achillion scientists highlight the potential of our approach as we continue to advance ACH-4471, our first small-molecule factor D inhibitor, through clinical development.”
Upcoming Poster Presentations
The research, presented by the poster titled “Evaluation of bacteria-mediated potential ‘Bystander’ hemolysis of PNH red cells in vitro: No evidence of significant complement classical or lectin pathway-mediated hemolysis induced by microorganisms,” showed that PNH red cells were not subjected to theoretical “bystander hemolysis” when incubated with the bacteria tested, suggesting no increased risk of pathogen-induced hemolytic breakthrough in PNH patients if treated with a complement alternative pathway (AP) inhibitor.
A second research, presented by the poster titled ‘Effect of complement inhibition by anti-C5 (eculizumab) or a small molecule inhibitor of Factor D (ACH-4471) on survival of meningococci in blood from vaccinated adults”, suggests that vaccination may be more effective in decreasing the risk of meningococcal disease in the presence of an AP inhibitor as compared to a C5 inhibitor.